Nicaise Ndembi
More than 21,000 people in Africa contracted mpox in 2024—a bad number that could have been much worse without the help of Nicaise Ndembi, then head of the Africa Centers for Disease Control and Prevention and now the deputy director general of the International Vaccine Institute (IVI). In his time at AfricaCDC, Ndembi led the continent-wide response to mpox—strengthening surveillance and screening and providing vaccines and medicinal therapeutics—and also established the Partnerships for African Vaccine Manufacturing, which created a framework for regional vaccine manufacturing and self-reliance. In his new role at the IVI, he will work to establish home-grown vaccine research and development, accelerating vaccine availability and distribution across Africa's 54 countries.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
14-05-2025
- Business Wire
TriLink BioTechnologies® and the International Vaccine Institute Sign a Memorandum of Understanding to Support the Development of mRNA-based Vaccines
SAN DIEGO--(BUSINESS WIRE)--Today, TriLink BioTechnologies (TriLink®), a Maravai® LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, and the International Vaccine Institute (IVI), a non-profit international organization devoted to and the discovery, development and delivery of vaccines for global health signed a Memorandum of Understanding to collaborate to advance the research and development of mRNA-based vaccines and promote equitable access to essential vaccines and health technologies. "This collaboration will not only advance the science of mRNA-based vaccines but may also significantly enhance access to life-saving vaccines in low- and middle-income countries (LMICs),' said Maravai and TriLink's Chief Commercial Officer, Becky Buzzeo. According to the terms of the MOU, TriLink and IVI will enter discussions on collaborative models to develop vaccines using mRNA technologies, facilitate knowledge exchange, and support joint scientific initiatives. "This collaboration will not only advance the science of mRNA-based vaccines but may also significantly enhance access to life-saving vaccines in low- and middle-income countries (LMICs),' said Maravai and TriLink's Chief Commercial Officer, Becky Buzzeo. 'By combining our expertise in nucleic acids with the International Vaccine Institute's global reach and commitment to public health, we are poised to profoundly impact global health equity. Together, we can accelerate the development and distribution of innovative mRNA vaccines, ensuring that more people, regardless of their geographic location, have access to the critical healthcare they need." Since its launch in 2017, TriLink's CleanCap® capping technology has continued to advance the mRNA capping industry and is used in the majority of all approved COVID-19 mRNA and saRNA vaccines. In 2024, TriLink expanded its products and services specifically for customers working in mRNA therapeutics, launching IVT enzymes, including CleanScribe™ RNA polymerase, which has been shown to reduce dsRNA, and opened its commercially ready GMP manufacturing facility in San Diego, California. IVI, based in Seoul, Korea, is an autonomous international organization established in 1997 as an initiative of the United Nations Development Program. It is dedicated exclusively to vaccines for global health, with a portfolio spanning all stages of pre-clinical and clinical development. Its work focuses on infectious diseases of global health importance, particularly those that disproportionately affect LMICs, including cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, and COVID-19. 'IVI is pleased to partner with TriLink BioTechnologies, a leading provider of life science reagents and services, including its proprietary capping technology that enhances mRNA stability and translation efficiency,' said Dr. Jerome Kim, Director General of IVI. 'This collaboration will empower the two organizations and our partners to accelerate the development and global delivery of advanced mRNA vaccines, especially to people in LMICs.' About TriLink BioTechnologies TriLink BioTechnologies, a Maravai LifeSciences company, is a global leader in nucleic acid and mRNA solutions. TriLink delivers unrivaled chemical and biological experience, CDMO services, and high-quality readymade and custom materials, including its patented CleanCap® mRNA capping technology. Pharmaceutical leaders, biotech disruptors, and world governments depend on TriLink to meet their greatest challenges, from delivering the COVID-19 vaccine at warp speed to empowering innovative treatments in oncology, infectious diseases, cardiology, and neurological disorders to enabling future pandemic response plans. For more information, visit About Maravai LifeSciences Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, and novel vaccines. Maravai's companies are leaders in providing products and services in the fields of nucleic acid synthesis and biologics safety testing to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. For more information about Maravai LifeSciences, visit About the International Vaccine Institute (IVI) The International Vaccine Institute (IVI) is a non-profit international organization established in 1997 at the initiative of the United Nations Development Programme with a mission to discover, develop, and deliver safe, effective, and affordable vaccines for global health. IVI's current portfolio includes vaccines at all stages of pre-clinical and clinical development for infectious diseases that disproportionately affect low- and middle-income countries, such as cholera, typhoid, chikungunya, shigella, salmonella, schistosomiasis, hepatitis E, HPV, COVID-19, and more. IVI developed the world's first low-cost oral cholera vaccine, pre-qualified by the World Health Organization (WHO), and developed a new-generation typhoid conjugate vaccine that also achieved WHO prequalification in early 2024. IVI is headquartered in Seoul, Republic of Korea with a Europe Regional Office in Sweden, an Africa Regional Office in Rwanda, a Country Office in Austria, and a Country and Project Office in Kenya. IVI additionally co-founded the Hong Kong Jockey Club Global Health Institute in Hong Kong and hosts Collaborating Centers in Ghana, Ethiopia, and Madagascar. 42 countries and the WHO are members of IVI, and the governments of the Republic of Korea, Sweden, India, Finland, Austria, and Thailand provide state funding. For more information, please visit
Time Magazine
08-05-2025
- Time Magazine
Nicaise Ndembi
More than 21,000 people in Africa contracted mpox in 2024—a bad number that could have been much worse without the help of Nicaise Ndembi, then head of the Africa Centers for Disease Control and Prevention and now the deputy director general of the International Vaccine Institute (IVI). In his time at AfricaCDC, Ndembi led the continent-wide response to mpox—strengthening surveillance and screening and providing vaccines and medicinal therapeutics—and also established the Partnerships for African Vaccine Manufacturing, which created a framework for regional vaccine manufacturing and self-reliance. In his new role at the IVI, he will work to establish home-grown vaccine research and development, accelerating vaccine availability and distribution across Africa's 54 countries.
Yahoo
08-05-2025
- Yahoo
Anti-Cancer MAbS Market Research Report 2025: Rising Cancer Incidence Spurs Demand for Targeted Anti-Cancer MAbS Treatments - Historic Trends and Forecasts, 2019-2024, 2024-2029F, 2034F
Explore the thriving Anti-Cancer mAbS market with rapid growth from $69.33B in 2024 to $109.88B by 2029 (CAGR 9.3%). Key drivers include rising cancer rates and innovations in drug delivery and AI. Leading companies are making strategic moves through clinical trials and partnerships. North America is currently dominant, with Asia Pacific set for rapid expansion. This report details size, growth, trends, and strategies crucial for success. Anti-Cancer MAbS Market Dublin, May 08, 2025 (GLOBE NEWSWIRE) -- The "Anti-Cancer MAbS Market Report 2025" has been added to offering. The anti-cancer monoclonal antibodies (mAbs) market is experiencing substantial growth, driven by increasing cancer incidence and demand for effective treatments. The market is projected to expand from $69.33 billion in 2024 to $109.88 billion by 2029, with a CAGR of 9.3%. Advancements in immunotherapy, the adoption of combination therapies, and innovative drug delivery technologies are significant contributors to this growth. Regionally, North America dominated the market in 2023, while Asia Pacific is set to be the fastest-growing region over the coming years. The market encompasses a wide array of mAbs such as avastin, Herceptin, and keytruda, valued at factory gate levels, covering the industrial transactions between manufacturers and subsequent business customers, not resale values further down the supply chain. Growth is propelled by the increasing prevalence of cancer, as evidenced by PubMed's 2022 report predicting 1.9 million new global cancer cases. With cancer affecting millions globally, targeted therapies like anticancer mAbs are in heightened demand. Furthermore, the escalation in clinical trials underpins market expansion, with noting a sharp rise in registered trials from 365,000 in 2021 to 452,604 in 2023. Industry players, including Y-mAbs Therapeutics Inc., are pioneering advances with clinical trials, such as the Phase I trial for GD2-Targeted Radioimmunotherapy. This trial evaluates the GD2-SADA therapy's potential in treating solid tumors like small cell lung cancer, harnessing a two-step radiation delivery method aimed at minimizing damage to healthy tissues. Innovation remains critical, typified by Roche Holding AG's 2022 launch of PHESGO, a combination treatment for HER2-positive breast cancer. PHESGO offers subcutaneous administration, a patient-friendly alternative to intravenous delivery, illustrating the industry's shift towards more convenient therapeutic options. The competitive landscape features major corporations like Amgen Inc., Merck & Co., Inc., and Roche, engaging in strategic partnerships and innovation to maintain market leadership. For instance, Merck's acquisition of Prometheus Biosciences Inc. for $10.8 billion enhances its immunology portfolio with the addition of PRA023, now termed MK-7240, focused on addressing autoimmune disorders. The anticancer mAbs market report provides a thorough overview of the sector, including market size, regional shares, and detailed segmentation. It highlights key players like Eli Lilly and Company, Bristol Myers Squibb, and Pfizer Inc., alongside the impact of biotechnology advances and artificial intelligence integration in drug discovery, pivotal in strengthening the market's trajectory. This comprehensive assessment signifies the market's dynamic nature and the myriad opportunities within, shaped by innovation, strategic alliances, and a growing need for effective cancer therapies across the globe. Key Attributes: Report Attribute Details No. of Pages 175 Forecast Period 2025 - 2029 Estimated Market Value (USD) in 2025 $76.92 Billion Forecasted Market Value (USD) by 2029 $109.88 Billion Compound Annual Growth Rate 9.3% Regions Covered Global Key Topics Covered: 1. Executive Summary 2. Anti-Cancer MAbS Market Characteristics 3. Anti-Cancer MAbS Market Trends and Strategies 4. Anti-Cancer MAbS Market - Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market 5. Global Anti-Cancer MAbS Growth Analysis and Strategic Analysis Framework 5.1. Global Anti-Cancer MAbS PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints) 5.2. Analysis of End Use Industries 5.3. Global Anti-Cancer MAbS Market Growth Rate Analysis 5.4. Global Anti-Cancer MAbS Historic Market Size and Growth, 2019-2024, Value ($ Billion) 5.5. Global Anti-Cancer MAbS Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion) 5.6. Global Anti-Cancer MAbS Total Addressable Market (TAM) 6. Anti-Cancer MAbS Market Segmentation 6.1. Global Anti-Cancer MAbS Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion 6.2. Global Anti-Cancer MAbS Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion 6.3. Global Anti-Cancer MAbS Market, Segmentation by End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion 7. Anti-Cancer MAbS Market Regional and Country Analysis 7.1. Global Anti-Cancer MAbS Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion 7.2. Global Anti-Cancer MAbS Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion Companies Featured Amgen Inc. Bristol Myers Squibb Company Eli Lilly and Company F. Hoffmann-La Roche Ltd. GlaxoSmithKline plc Johnson & Johnson Novartis AG Merck & Co. Inc. Spectrum Pharmaceuticals Inc. AstraZeneca plc. Pfizer Inc. Gilead Sciences Inc. Bayer HealthCare ImmunoGen Inc. Genentech Inc. AbbVie Inc. Takeda Pharmaceuticals Seattle Genetics Regeneron Pharmaceuticals Celgene Ipsen Daiichi Sankyo Kite Pharma ADC Therapeutics MacroGenics Inc. BioXcel Therapeutics Zymeworks Inc. Exelixis Inc. Blueprint Medicines Erytech Pharma Oncopeptides AB For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment Anti-Cancer MAbS Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
